ATE211931T1 - Topoisomerase inhibitoren zur restenose- prevention - Google Patents

Topoisomerase inhibitoren zur restenose- prevention

Info

Publication number
ATE211931T1
ATE211931T1 AT99933575T AT99933575T ATE211931T1 AT E211931 T1 ATE211931 T1 AT E211931T1 AT 99933575 T AT99933575 T AT 99933575T AT 99933575 T AT99933575 T AT 99933575T AT E211931 T1 ATE211931 T1 AT E211931T1
Authority
AT
Austria
Prior art keywords
restenose
prevention
topoisomerase inhibitors
topoisomerase inhibitor
inhibitng
Prior art date
Application number
AT99933575T
Other languages
English (en)
Inventor
Robert Eury
Angelica Alvarado
Irina Pomerantseva
Michael Froix
Original Assignee
Quanam Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanam Medical Corp filed Critical Quanam Medical Corp
Application granted granted Critical
Publication of ATE211931T1 publication Critical patent/ATE211931T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99933575T 1998-06-26 1999-06-24 Topoisomerase inhibitoren zur restenose- prevention ATE211931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9076498P 1998-06-26 1998-06-26
PCT/US1999/014386 WO2000000238A1 (en) 1998-06-26 1999-06-24 Topoisomerase inhibitors for prevention of restenosis

Publications (1)

Publication Number Publication Date
ATE211931T1 true ATE211931T1 (de) 2002-02-15

Family

ID=22224203

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99933575T ATE211931T1 (de) 1998-06-26 1999-06-24 Topoisomerase inhibitoren zur restenose- prevention

Country Status (7)

Country Link
US (1) US20020004679A1 (de)
EP (1) EP1087801B1 (de)
JP (1) JP2002519335A (de)
AT (1) ATE211931T1 (de)
CA (1) CA2335842A1 (de)
DE (1) DE69900689T2 (de)
WO (1) WO2000000238A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627209B2 (en) * 1998-08-03 2003-09-30 W. Jerry Easterling Surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents
JP4898991B2 (ja) * 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー 被覆付植込式医療装置
US8883856B2 (en) 2000-02-28 2014-11-11 John Jackson Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
AU2001240024A1 (en) * 2000-03-31 2001-10-15 Supergen, Inc. Camptothecin complexes
US6572648B1 (en) * 2000-06-30 2003-06-03 Vascular Architects, Inc. Endoluminal prosthesis and tissue separation condition treatment method
WO2002032400A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6979347B1 (en) * 2000-10-23 2005-12-27 Advanced Cardiovascular Systems, Inc. Implantable drug delivery prosthesis
US6758859B1 (en) * 2000-10-30 2004-07-06 Kenny L. Dang Increased drug-loading and reduced stress drug delivery device
WO2002056872A2 (en) * 2000-10-31 2002-07-25 Chemgenex Therapeutics, Inc. Antiproliferative colchicine compositions and uses thereof
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7041046B2 (en) 2001-05-07 2006-05-09 Xoft, Inc. Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
US7651695B2 (en) * 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
FI20021570A0 (fi) * 2002-09-03 2002-09-03 Gallen Kallela Siren Janne Päällystetyn kirurgisen stentin paranneltu rakenne
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7135038B1 (en) 2002-09-30 2006-11-14 Advanced Cardiovascular Systems, Inc. Drug eluting stent
US20050165469A1 (en) * 2002-12-24 2005-07-28 Michael Hogendijk Vascular prosthesis including torsional stabilizer and methods of use
US7846198B2 (en) * 2002-12-24 2010-12-07 Novostent Corporation Vascular prosthesis and methods of use
US20070037739A1 (en) * 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
US8828416B2 (en) * 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US20070184085A1 (en) * 2006-02-03 2007-08-09 Boston Scientific Scimed, Inc. Ultrasound activated medical device
ATE480206T1 (de) * 2006-03-03 2010-09-15 Prescient Medical Inc Endoluminale prothese zur behandlung von empfindlicher plaque
US20070225795A1 (en) * 2006-03-24 2007-09-27 Juan Granada Composite vascular prosthesis
US20080140182A1 (en) * 2006-04-28 2008-06-12 Patricia Scheller Composite endoluminal prostheses for treating vulnerable plaque
DE102006038241A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Stent mit einer genisteinhaltigen Beschichtung oder Kavitätenfüllung
CA2672496A1 (en) * 2006-12-13 2008-06-19 Angiotech Pharmaceuticals, Inc. Medical implants with a combination of compounds
US8348994B2 (en) * 2007-03-09 2013-01-08 Novostent Corporation Vascular prosthesis with alternating helical sections
US8002815B2 (en) * 2007-03-09 2011-08-23 Novostent Corporation Delivery system and method for vascular prosthesis
US8425586B2 (en) * 2009-09-02 2013-04-23 Novostent Corporation Vascular prosthesis with stress relief slots
EP2475336A1 (de) * 2009-09-10 2012-07-18 NovoStent Corporation Gefässprothesenanordnung mit haltemechanismus und verfahren dafür
CA3037168A1 (en) 2009-12-18 2011-06-23 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
USD665500S1 (en) 2011-04-15 2012-08-14 Novostent Corporation Stent
KR101786020B1 (ko) * 2015-12-24 2017-10-17 전남대학교병원 펨토초 레이저 가공을 통한 재협착 억제 및 재내피화 촉진용 스텐트 및 이의 제조 방법
WO2019222843A1 (en) 2018-05-22 2019-11-28 Interface Biologics, Inc. Compositions and methods for delivering drugs to a vessel wall

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5569197A (en) * 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
WO1998017331A1 (en) * 1995-06-07 1998-04-30 Cook Incorporated Silver implantable medical device
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen

Also Published As

Publication number Publication date
US20020004679A1 (en) 2002-01-10
JP2002519335A (ja) 2002-07-02
EP1087801A1 (de) 2001-04-04
DE69900689D1 (en) 2002-02-21
DE69900689T2 (de) 2002-08-29
WO2000000238A1 (en) 2000-01-06
EP1087801B1 (de) 2002-01-16
CA2335842A1 (en) 2000-01-06
WO2000000238A9 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
ATE211931T1 (de) Topoisomerase inhibitoren zur restenose- prevention
DE69925133D1 (de) Pyrrolobenzodiazepine
AU5414000A (en) Compounds
MY138239A (en) Nitrogen containing heterobicycles as factor xa inhibitors
TR200103094T2 (tr) ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
AU2001278870A1 (en) Equipment and techniques for increasing the dynamic range of a projection system
MXPA03000136A (es) Derivados anticonvulsivos utiles para prevenir el desarrollo de la diabetes mellitus de tipo ii o del sindromex.
AU2003245540A1 (en) Wireless network access point configuration
WO2002030353A3 (en) NF-λB INHIBITORS
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
PT883405E (pt) Inibidores de amidino-protease
IL144234A0 (en) Synthesis method of nitroxymethylphenyl esters of aspirin derivatives
AU2003290592A1 (en) Antitumor benzoylsulfonamides
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
GB2331988B (en) Polycyclic sulphamate inhibitors or oestrone sulphatase
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
HRP20041075B1 (hr) Postupak priprave olanzapina i njegovog intermedijera
WO2000047197A3 (en) Alkylating agents for treatment of cellular proliferation
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
MY140504A (en) Statin-mmp inhibitor combinations
EP1202628A4 (de) Hypoxanthin- und thiohypxanthin-verbindungen
EP1351680B8 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties